Página principal > Resultados de la búsqueda: Deniz, Yamo
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 5 registros encontrados en 0.02 segundos.
Artículos, Encontrados 5 registros
Artículos Encontrados 5 registros  
1.
13 p, 1.1 MB Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose / Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Rabe, Klaus F. (Observational and Pragmatic Research Institute) ; Price, David (Universitair Ziekenhuis Gent) ; Brusselle, Guy (National Jewish Health) ; Wechsler, Michael E. (Regeneron Pharmaceuticals Inc.) ; Xia, Changming (Sanofi) ; Pandit-Abid, Nami (Sanofi) ; Gall, Rebecca (Regeneron Pharmaceuticals Inc.) ; Rowe, Paul J. (Sanofi) ; Deniz, Yamo (Regeneron Pharmaceuticals Inc.) ; Jacob-Nara, Juby A. (Sanofi) ; Radwan, Amr (Regeneron Pharmaceuticals Inc.) ; Universitat Autònoma de Barcelona
Dupilumab has been shown to improve clinical outcomes long term while reducing oral corticosteroid (OCS) dose in patients with severe OCS-dependent asthma. This post hoc analysis assesses the impact of OCS dose at baseline (≤10 or >10 mg·day −1) on long-term outcomes of dupilumab treatment. [...]
2023 - 10.1183/23120541.00056-2023
ERJ Open Research, Vol. 9 (november 2023)  
Registro completo - Creative Commons
2.
11 p, 2.6 MB Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma / Papi, Alberto (University Hospital) ; Corren, Jonathan (David Geffen School of Medicine at UCLA) ; Castro, Mario (University of Kansas School of Medicine) ; Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Rogers, Linda (Icahn School of Medicine at Mount Sinai) ; Chapman, Kenneth R. (University of Toronto) ; Jackson, Daniel J. (University of Wisconsin School of Medicine and Public Health) ; Daizadeh, Nadia (Sanofi) ; Pandit-Abid, Nami (Sanofi) ; Gall, Rebecca (Regeneron Pharmaceuticals. Inc) ; Jacob-Nara, Juby A. (Sanofi) ; Rowe, Paul J. (Sanofi) ; Deniz, Yamo (Regeneron Pharmaceuticals. Inc) ; Ortiz, Benjamin (Regeneron Pharmaceuticals. Inc) ; Universitat Autònoma de Barcelona
Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced expiratory volume in 1 s (FEV) in patients with moderate-to-severe asthma and elevated type 2 biomarkers from phase 3 LIBERTY ASTHMA QUEST (NCT02414854). [...]
2022 - 10.1111/all.15456
Allergy, Vol. 78 (august 2022) , p. 233-243  
Registro completo - Creative Commons
3.
4 p, 302.7 KB Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation / Hanania, Nicola A (Baylor College of Medicine) ; Maspero, Jorge F (Fundación CIDEA) ; Halpin, David M G (University of Exeter) ; Jackson, David J (Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Foundation Trust) ; Panettieri, Reynold A (The State University of New Jersey) ; Castro, Mario (University of Kansas School of Medicine) ; Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Daizadeh, Nadia (Sanofi) ; Gall, Rebecca (Regeneron Pharmaceuticals. Inc) ; Jacob-Nara, Juby A (Sanofi) ; Ortiz, Benjamin (Regeneron Pharmaceuticals. Inc) ; Djandji, Michel (Sanofi) ; Rowe, Paul J (Sanofi) ; Deniz, Yamo (Regeneron Pharmaceuticals. Inc) ; Universitat Autònoma de Barcelona
2022 - 10.2147/JAA.S354013
Journal of Asthma and Allergy, Vol. 15 (june 2022) , p. 851-854  
Registro completo - Creative Commons
4.
9 p, 430.4 KB Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose / Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Maspero, Jorge F (Fundación CIDEA) ; Castro, Mario (University of Kansas School of Medicine) ; Hanania, Nicola A. (Baylor College of Medicine) ; Ford, Linda B (Asthma & Allergy Center) ; Halpin, David M G (College of Medicine and Health) ; Jackson, David J (King's College London) ; Daizadeh, Nadia (Sanofi-Syntelabo) ; Djandji, Michel (Sanofi-Syntelabo) ; Mitchell, Colin P (Sanofi-Syntelabo) ; Crikelair, Nora (Regeneron Pharmaceuticals. Inc) ; Jacob-Nara, Juby A (Sanofi-Syntelabo) ; Deniz, Yamo (Regeneron Pharmaceuticals. Inc) ; Rowe, Paul J (Sanofi-Syntelabo) ; Ortiz, Benjamin (Regeneron Pharmaceuticals. Inc) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation in multiple diseases. In the phase 3 LIBERTY ASTHMA VENTURE (VENTURE) study (NCT02528214), dupilumab versus placebo reduced oral corticosteroid (OCS) dose and improved clinical outcomes in patients with OCS-dependent severe asthma. [...]
2022 - 10.1016/j.jaip.2022.03.020
The Journal of allergy and clinical immunology. In practice, Vol. 10 Núm. 7 (July 2022) , p. 1835-1843  
Registro completo - Creative Commons
5.
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma / Papadoppoulos, Nikolaos G. (University of Athens) ; Szefler, Stanley J. (The University of Colorado School of Medicine and Children's Hospital Colorado) ; Bacharier, Leonard B. (Vanderbilt University Medical Center) ; Maspero, Jorge F (Fundación CIDEA, Buenos Aires) ; Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Fiocchi, Alessandro (University of Athens) ; Lee, Jason K. (Toronto Allergy and Asthma Clinic) ; Daizadeh, Nadia (Sanofi, Cambridge (MA)) ; Lederer, David J. (Regeneron Pharmaceuticals. Inc) ; Hardin, Megan (Sanofi, Cambridge (MA)) ; Gall, Rebecca (Regeneron Pharmaceuticals. Inc) ; Djandji, Michel (Sanofi, Cambridge (MA)) ; Siddiqui, Shahid (Regeneron Pharmaceuticals. Inc) ; Jacob-Nara, Juby A (Sanofi, Cambridge (MA)) ; Deniz, Yamo (Regeneron Pharmaceuticals. Inc) ; Rowe, Paul J. (Sanofi, Cambridge (MA))
Wiley-Blackwell, 2023 - 10.1111/all.15743
Allergy  
Registro completo -

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos